William Blair & Company
REGN icon

William Blair & Company’s Regeneron Pharmaceuticals REGN Stock Holding History

William Blair & Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
1,364
+66
+5% +$50.5K ﹤0.01% 927
2025
Q4 		$1M Buy
1,298
+29
+2% +$19.7K ﹤0.01% 941
2025
Q3 		$714K Buy
1,269
+12
+1% +$6.79K ﹤0.01% 1003
2025
Q2 		$660K Sell
1,257
-25
-2% -$14K ﹤0.01% 1006
2025
Q1 		$813K Buy
1,282
+27
+2% +$18.6K ﹤0.01% 946
2024
Q4 		$894K Sell
1,255
-788
-39% -$661K ﹤0.01% 932
2024
Q3 		$2.15M Buy
2,043
+58
+3% +$64.5K 0.01% 691
2024
Q2 		$2.09M Sell
1,985
-39
-2% -$37.8K 0.01% 674
2024
Q1 		$1.95M Buy
2,024
+8
+0.4% +$7.61K 0.01% 684
2023
Q4 		$1.77M Buy
2,016
+456
+29% +$376K 0.01% 699
2023
Q3 		$1.28M Sell
1,560
-225
-13% -$177K ﹤0.01% 766
2023
Q2 		$1.28M Sell
1,785
-183
-9% -$141K ﹤0.01% 767
2023
Q1 		$1.62M Sell
1,968
-413
-17% -$311K 0.01% 705
2022
Q4 		$1.72M Buy
2,381
+1,133
+91% +$836K 0.01% 671
2022
Q3 		$860K Buy
1,248
+121
+11% +$76.2K ﹤0.01% 865
2022
Q2 		$666K Sell
1,127
-304
-21% -$198K ﹤0.01% 974
2022
Q1 		$999K Buy
1,431
+222
+18% +$140K ﹤0.01% 922
2021
Q4 		$764K Sell
1,209
-505
-29% -$310K ﹤0.01% 1054
2021
Q3 		$1.04M Sell
1,714
-128
-7% -$79.5K ﹤0.01% 912
2021
Q2 		$1.03M Buy
1,842
+59
+3% +$29.9K ﹤0.01% 909
2021
Q1 		$844K Buy
1,783
+532
+43% +$259K ﹤0.01% 953
2020
Q4 		$604K Sell
1,251
-270
-18% -$146K ﹤0.01% 1031
2020
Q3 		$851K Buy
1,521
+173
+13% +$105K ﹤0.01% 801
2020
Q2 		$841K Buy
1,348
+138
+11% +$78.3K ﹤0.01% 771
2020
Q1 		$591K Buy
1,210
+104
+9% +$42.9K ﹤0.01% 822
2019
Q4 		$415K Sell
1,106
-367
-25% -$123K ﹤0.01% 1058
2019
Q3 		$409K Sell
1,473
-184
-11% -$54.4K ﹤0.01% 1008
2019
Q2 		$519K Buy
1,657
+50
+3% +$16.6K ﹤0.01% 965
2019
Q1 		$660K Buy
1,607
+432
+37% +$178K ﹤0.01% 864
2018
Q4 		$439K Buy
1,175
+20
+2% +$7.32K ﹤0.01% 955
2018
Q3 		$467K Hold
1,155
– – ﹤0.01% 977
2018
Q2 		$398K Sell
1,155
-818
-41% -$256K ﹤0.01% 1023
2018
Q1 		$679K Sell
1,973
-9
-0.5% -$3.13K ﹤0.01% 822
2017
Q4 		$745K Buy
1,982
+142
+8% +$57.5K 0.01% 832
2017
Q3 		$823K Buy
1,840
+127
+7% +$60.4K 0.01% 779
2017
Q2 		$841K Buy
1,713
+79
+5% +$34.6K 0.01% 804
2017
Q1 		$612K Buy
1,634
+226
+16% +$83.8K ﹤0.01% 842
2016
Q4 		$517K Buy
1,408
+59
+4% +$22.4K ﹤0.01% 827
2016
Q3 		$542K Buy
1,349
+179
+15% +$71.8K ﹤0.01% 803
2016
Q2 		$409K Buy
1,170
+576
+97% +$222K ﹤0.01% 869
2016
Q1 		$214K Sell
594
-1,489
-71% -$614K ﹤0.01% 1049
2015
Q4 		$1.13M Buy
2,083
+1,454
+231% +$788K 0.01% 596
2015
Q3 		$292K Sell
629
-49
-7% -$26.3K ﹤0.01% 1153
2015
Q2 		$345K Sell
678
-151
-18% -$73.7K ﹤0.01% 1883
2015
Q1 		$374K Buy
829
+37
+5% +$15.7K ﹤0.01% 1819
2014
Q4 		$324K Buy
792
+92
+13% +$36.2K ﹤0.01% 1828
2014
Q3 		$252K Buy
+700
New +$235K ﹤0.01% 1899
2014
Q2 		– Sell
-1,243
Closed -$373K – 2109
2014
Q1 		$373K Buy
+1,243
New +$383K ﹤0.01% 1704

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

William Blair & Company's REGN Position: Q1 2026 in Review

William Blair & Company increased its Regeneron Pharmaceuticals (REGN) stake by 5.1% in Q1 2026, buying an estimated $50.5K and bringing the position to 1,364 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #927.

William Blair & Company first reported a position in REGN in Q1 2014 and has held it in 48 quarters since. The position peaked at $2.15M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • William Blair & Company held 1,364 shares of Regeneron Pharmaceuticals worth $1.05M as of Q1 2026.
  • William Blair & Company bought 66 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $50.5K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #927 holding.
  • William Blair & Company first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 48 quarters since.
  • William Blair & Company's Regeneron Pharmaceuticals position peaked at $2.15M in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.